Sign Up
OverviewAPI
AIDS Healthcare Foundation (AHF) is calling out Gilead Sciences for its profit-driven decisions and high prices for lifesaving drugs. AHF highlights Gilead's patent manipulation, price hikes, and suppression of safer drug formulations. The company's Q4 2023 earnings show flat sales except for Veklury, indicating a focus on profit over patient access. AHF urges responsible investors to divest from Gilead stock.

Ask a question